Navigation Links
UT-Battelle licenses tissue regeneration technologies to NellOne Therapeutics, Inc.
Date:1/28/2010

OAK RIDGE, Tenn., Jan. 28, 2010 -- In a major step toward commercialization of a promising therapeutic treatment, Oak Ridge National Laboratory contractor UT-Battelle has exclusively licensed patents on inventions based on the Nell-1 gene to NellOne Therapeutics, Inc. (NellOne), a company spun out of the Department of Energy laboratory.

The protein therapy treatment under development takes advantage of the Nell-1 gene's cell-signaling pathway that controls tissue growth and maturation in mammalian organs.

The foundation for this therapy is research performed by Cymbeline Culiat, who as an ORNL systems genetics researcher identified the role that the Nell-1 pathway plays in tissue growth and maturation.

Today, Culiat is leading the NellOne research effort to translate the Nell-1 pathway discoveries into a therapy that restores both mass and function to damaged human tissues, such as heart and skeletal muscle.

If successful, the protein therapy could improve the lives of victims of heart attacks and severe muscle wounds. Other therapies, such as stem-cell treatments, have succeeded in triggering tissue formation but fall short in restoring the actual function of the tissue.

Battelle Ventures, with its Knoxville-based affiliate fund, Innovation Valley Partners (IVP), created NellOne with a $1.5-million seed investment in 2008.

"Our executing this license is confirmation from NellOne that sufficient proof-of-principle experiments have been completed and that the company is progressing toward the commercialization of an extremely promising technology that could one day vastly improve the lives of countless heart patients," said Tracy Warren, NellOne chief executive officer and Battelle Ventures general partner.

"NellOne is currently dedicated to the development of intellectual property and moving into a clinical setting," Warren continued, noting that it operates out of the IVP office in Knoxville. "A medical treatment based on the patented technologies is years away, making Battelle Ventures' support even more critical."

"This licensing agreement is a statement not only of NellOne's promise, but also of how vital the support of venture capital investment is during these crucial early years of technology development and nurturing," said ORNL Partnerships Director Tom Ballard. "This announcement is an important step along the way to the marketplace past the initial proof-of-concept stage."


'/>"/>

Contact: Bill Cabage
cabagewh@ornl.gov
865-574-4399
DOE/Oak Ridge National Laboratory
Source:Eurekalert

Related biology news :

1. Virginia Tech licenses GenoCAD source code to ISCB
2. TAXIS Pharmaceuticals licenses novel antimicrobial technology from Rutgers and UMDNJ
3. MSU licenses plant oil enhancement technology to BASF Plant Science
4. UGA licenses technology to make fuel from dead forests and agricultural waste
5. UGA licenses new Bermuda grass that thrives in sun and shade
6. UGA licenses invention that kills food-borne pathogens in minutes
7. Ocera Therapeutics licenses novel treatment for acute hepatic encephalopathy from UCLB
8. Syntermed licenses Emory ERTb software for enhanced cardiac imaging
9. $3.75 million grant advances tissue engineering partnership
10. New pathway discovered that may prevent tissue damage resulting from inflammation
11. Supportive materials will help regenerate heart tissue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... June 2, 2016 The Department of ... awarded the 44 million US Dollar project, for the ... Plates including Personalization, Enrolment, and IT Infrastructure , ... the production and implementation of Identity Management Solutions. Numerous renowned ... Decatur was selected for the most ...
(Date:6/1/2016)... 1, 2016 Favorable Government Initiatives ... and Criminal Identification to Boost Global Biometrics System Market ... TechSci Research report, " Global Biometrics Market By ... and Opportunities, 2011 - 2021", the global biometrics market ... on account of growing security concerns across various end ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC ... today announced the opening of an IoT Center of ... strengthen and expand the development of embedded iris biometric ... unprecedented level of convenience and security with unmatched biometric ... one,s identity aside from DNA. EyeLock,s platform uses video ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) ... precise treatments and faster cures for prostate cancer. Members of the Class of ... 15 countries. Read More About the Class of 2016 ... ... ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... In a ... Hospital in Denmark detail how a patient who developed lymphedema after being treated for ... The results could change the paradigm for dealing with this debilitating, frequent side effect ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the ... Convention Center and will showcase its product’s latest features from June 26 to ... a scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
Breaking Biology Technology: